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Exercise increases glucose uptake in skeletal muscle in-
dependently of insulin signaling. This makes exercise an
effective stimulus to increase glucose uptake in insulin-
resistant skeletal muscle. AMPK has been suggested to
regulate muscle glucose uptake during exercise/contrac-
tion, but ﬁndings fromstudies of various AMPK transgenic
animals have not reached consensus on this matter.
Comparing methods used in these studies reveals a hith-
erto unappreciated difference between those studies
reporting a role of AMPK and those that do not. This
led us to test the hypothesis that AMPK and downstream
target TBC1D1 are involved in regulating muscle glucose
uptake in the immediate period after exercise/contraction
but not during exercise/contraction. Here we demon-
strate that glucose uptake during exercise/contraction
was not compromised in AMPK-deﬁcient skeletal muscle,
whereas reversal of glucose uptake toward resting levels
after exercise/contraction wasmarkedly faster in AMPK-
deﬁcient muscle compared with wild-type muscle.
Moreover, muscle glucose uptake after contraction was
positively associated with phosphorylation of TBC1D1,
and skeletal muscle from TBC1D1-deﬁcient mice dis-
played impaired glucose uptake after contraction. These
ﬁndings reconcile previous observed discrepancies and
redeﬁne the role of AMPK activation during exercise/con-
traction as being important for maintaining glucose per-
meability in skeletal muscle in the period after, but not
during, exercise/contraction.
To meet the increased energy demand in skeletal muscle
during exercise and contraction, glucose uptake is
markedly increased. After the cessation of exercise and
contraction, energy demand decreases and muscle glucose
uptake gradually returns to resting levels (1–5). Studies
have shown that exercise/contraction uses mechanisms to
increase muscle glucose uptake that are independent of
those engaged upon insulin stimulation (6–8). It has been
speculated that cellular feed-forward events secure the
initial rise in glucose uptake upon initiation of exercise/
contraction, whereas other events control glucose uptake
during exercise/contraction based on cellular feedback
signals (9). Along these lines, the reversal of glucose uptake
after cessation of exercise/contraction is likely also a reg-
ulated process securing adequate cellular fuel supply in
recovery. However, the nature of this process is still only
weakly understood.
Skeletal muscle glucose uptake can be deﬁned as a three-
step process involving delivery, transport, and metabolism
of glucose (10,11). During exercise, the glucose transport
capacity is mainly determined by the representation of
GLUT4 at the cell surface membrane that is regulated by
both exo- and endocytotic processes (12). It is well known
that pharmacological activation of the cellular energy
sensor AMPK is sufﬁcient to increase glucose uptake
and GLUT4 representation at the cell surface membrane of
skeletal muscle (13). An obvious extrapolation of these
observations has been to assume that the AMPK activation
seen in skeletal muscle during exercise/contractile activity
(14,15) is regulating glucose uptake under these conditions
as well. However, despite numerous studies, no consensus
on the role of AMPK in regulating muscle glucose uptake
during exercise/contractile activity has been reached (16).
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Going through the literature, we observed an unappre-
ciated methodological difference between those studies
reporting impairments in exercise/contraction-induced
muscle glucose uptake by ablation of AMPK activity in
skeletal muscle and those studies that did not. In the
majority of studies reporting decreased muscle glucose
uptake with contraction, the actual assessment of glucose
uptake by muscle tracer accumulation took place either
in the period during as well as in the period after con-
traction (17,18) or solely in the period after contraction
(17,19–23). Moreover, studies have suggested that phar-
macological agents activating AMPK increase muscle glu-
cose uptake by slowing down GLUT4 endocytosis, whereas
insulin and contraction increases glucose uptake by en-
hancing GLUT4 exocytosis (24–26). Inspired by these
observations, we tested the hypothesis that the increase
in glucose uptake during exercise/contractile activity
occurs independently of AMPK, whereas AMPK becomes
key for maintaining muscle glucose uptake in the period
after exercise/contractile activity. Herein, using both con-
ventional and conditional AMPKa1a2 muscle-speciﬁc
double-knockout (mdKO) mice as well as whole-body
TBC1D1 KO mice, we demonstrate that AMPK is not
necessary for contraction to increase muscle glucose up-
take. In contrast, we provide evidence to support that
AMPK regulates muscle glucose uptake in the immediate
period after exercise/contraction and that this is likely
mediated by phosphorylation of its downstream target
TBC1D1. Collectively, these results redeﬁne the biological
role of AMPK and TBC1D1 signaling in the context of
skeletal muscle glucose uptake.
RESEARCH DESIGN AND METHODS
Animals
All animal experiments were approved by the Danish Animal
Experiments Inspectorate and complied with the EU con-
vention for the protection of vertebrates used for scientiﬁc
purposes. Animals used in this study were conventional and
conditional (inducible) AMPKa1a2 mdKO and recombinant
congenic TBC1D1-deﬁcient (whole-body TBC1D1 KO) female
mice with corresponding wild-type (WT) littermates as con-
trols (27–29). Mice (166 2 weeks [mean6 SD]) were group
housed at two animal facilities at the Department of Exper-
imental Medicine and kept in a temperature- and humidity-
controlled room on a 12:12 h light-dark cycle with free access
to standard rodent chow and water.
Muscle Glucose Uptake After Exercise
All mice were acclimatized to treadmill running and sub-
sequently subjected to a graded maximal running test as
previously described (30). For muscle glucose uptake mea-
surements after exercise, mice were fasted in single cages
for 2 h before either performing a single bout of treadmill
exercise (30 min, 10° incline, and 60% of maximal running
speed) or resting as sedentary controls. Immediately after
rest/exercise, mice were anesthetized by an intraperitoneal
injection of pentobarbital (9 mg/100 g body weight) and
left to recover on a heating plate (30°C) for 30 min.
Hereafter, a bolus of [3H]2-deoxyglucose (12.3 MBq/kg
body weight) dissolved in isotonic saline was administered
retroorbitally. After 10 min, during which blood sampling
was performed at time points 0, 5, and 10 min, tibialis
anterior (TA) and extensor digitorum longus (EDL)
muscles were rapidly dissected and frozen for analysis
of muscle glucose uptake as previously described (31).
Muscle Glucose Uptake During and After In Situ
Contraction
Glucose uptake in TA and EDL muscles during in situ
contraction was determined as previously described (31).
In short, an electrode was placed on the common peroneal
nerve of one leg of anesthetized animals (intraperitoneal
injection of pentobarbital, 9 mg/100 g body weight), after
which electrical stimulation was applied for 10 min to
initiate contraction of the TA and EDL muscles. The other
leg served as a sham-operated control. Muscle glucose
uptake during in situ contraction was determined by retro-
orbital injection of [3H]2-deoxyglucose as described above.
For muscle glucose uptake measurements after in situ
contraction, anesthetized and muscle-contracted animals
were left to recover on a heating plate (30°C) for 30 or
60 min, after which muscle glucose uptake was determined
as described above.
Insulin-Stimulated Glucose Uptake of Incubated
Skeletal Muscle
Fed animals were anesthetized by an intraperitoneal in-
jection of pentobarbital (10 mg/100 g body weight) before
EDL muscles were isolated and suspended in incubation
chambers containing Krebs-Ringer buffer (KRB) as pre-
viously described (31). In short, EDL muscles were
incubated for 30 min in the absence or presence of
100 mU/mL insulin, after which half of the muscles
were transferred to new incubation chambers containing
KRB for either 30 min or 1 h. 2-Deoxyglucose uptake was
measured during a 10-min period after the respective
incubation period by adding 1 mmol/L [3H]2-deoxyglucose
(0.028 MBq/mL) and 7 mmol/L [14C]mannitol (0.0083
MBq/mL) to the incubation medium. 2-Deoxyglucose up-
take was determined as previously described (31).
Glucose Uptake in Incubated Skeletal Muscle 2 h After
Prior In Situ Contraction
After in situ contraction of a single mouse hind limb, EDL
muscles from both legs were isolated and incubated in
incubation chambers with KRB as described above.
2-Deoxyglucose uptake was measured during the last
10 min of the 2-h incubation period by adding 1 mmol/L
[3H]2-deoxyglucose (0.028 MBq/mL) and 7 mmol/L
[14C]mannitol (0.0083 MBq/mL) to the incubation me-
dium. During the incubation period, KRB was replaced at
time points 30, 60, and 90 min to minimize ﬂuctuations
in energy substrate content (pyruvate) of the KRB.
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Muscle Processing, SDS-PAGE, and Western Blot
Analyses
Muscles were homogenized as previously described (31,32),
and lysates were collected and frozen in liquid nitrogen for
subsequent analyses. The bicinchoninic acid method was used
to determine total protein abundance inmuscle lysates. Lysates
were boiled in Laemmli buffer and subjected to SDS-PAGE and
immunoblotting as previously described (31,32).
AMPK Activity
Heterotrimer-speciﬁc AMPK activity in skeletal muscle was
determined by three consecutive immunoprecipitations as
previously described (31,32).
Muscle Glycogen and Glucose-6-phosphate
Muscle glycogen was measured on muscle protein homog-
enate after acid hydrolysis as previously described (31).
Muscle glucose-6-phosphate content was measured ﬂuoro-
metrically as described by Lowry and Passonneau (33).
Antibodies
Primary antibodies against pAMPKa-Thr172 (2531), pACC-
Ser79/212 (3661), pTBC1D4-Thr642 (8881), pErk1/2-
Thr202/Tyr204 (9101), pP38MAPK-Thr180/Tyr182 (9211),
Erk1/2 (9102), P38MAPK (9212), GAPDH (2118), and
TBC1D1 (4629) were from Cell Signaling Technology. Anti-
bodies against pTBC1D1-Ser231 (07-2268) and TBC1D4
(AS160) (07-741) were from Millipore, and AMPKa2 (SC-
19131), hexokinase II (SC-6512), and GLUT4 (PA1-1065)
antibodies were from Santa Cruz Biotechnology and Thermo
Fisher Scientiﬁc, respectively. ACC protein was detected using
horseradish peroxidase–conjugated streptavidin from Dako
(P0397). AMPKa1 protein were detected using antibody as
previously described (30,34). Antibodies used for the AMPK
activity assay were raised against AMPKg3 (provided by D.G.
Hardie, University of Dundee, Scotland, U.K.), AMPKa2 (SC-
19131; Santa Cruz Biotechnology), and AMPKa1 (purchased
from GenScript, Jiangning, Nanjing, China).
Statistical Analyses
Statistical analyses were performed using SigmaPlot (version
13.0; SYSTAT, Erkrath, Germany). Data are presented as the
means 6 SEM unless stated otherwise. Two-way ANOVA
with and without repeated measures was used to assess
statistical differences. In case of unequal variance (Fig. 1E
and G), the two-sided Student t test was used to assess
statistical difference between groups. The Student-Newman-
Keuls test was used for post hoc testing. Correlation analyses
were performed by calculating the Pearson product moment
correlation. Statistical signiﬁcance was deﬁned as P , 0.05.
RESULTS
Glucose Uptake Is Decreased in AMPK-Deﬁcient
Muscle in Recovery From Exercise and Contraction
We have previously shown that glucose uptake during
in vivo exercise is intact in skeletal muscle from conven-
tional AMPKa1a2 mdKO mice (30). However, when eval-
uating muscle glucose uptake 30 min after in vivo exercise,
we found that glucose uptake was signiﬁcantly lower in
skeletal muscle from AMPKa1a2 mdKO mice compared
with WT littermates (Fig. 1A). We next sought to demon-
strate whether reductions in muscle glucose uptake after
in vivo exercise were imitated in a well-controlled exper-
imental setup using nerve stimulation to elicit in situ
muscle contraction in anesthetized mice. Again, we found
that glucose uptake during in situ contraction was similar
in muscle of WT and AMPKa1a2 mdKO mice, whereas
glucose uptake was signiﬁcantly decreased in skeletal
muscle from AMPKa1a2 mdKO mice compared with
WT mice 30 min and 1 h after contraction (Fig. 1B). We
conﬁrmed this phenotype in skeletal muscle of the in-
ducible AMPKa1a2 mdKO model (Fig. 1C and Supple-
mentary Fig. 1A), ensuring that the phenotype observed in
the conventional AMPKa1a2 mdKO model is unlikely to
be associated with secondary adaptations caused by em-
bryonic AMPKa1a2 deletion. The in situ contraction pro-
tocol reduced glycogen content (Fig. 1D and E) and
increased phosphorylation of Erk1/2 Thr202/Tyr204
and p38 MAPK Thr180/Tyr182 (Fig. 1F–H) in skeletal
muscle to an extent that did not differ between genotypes.
This indicates that the in situ contraction protocol induced
comparable changes in skeletal muscle from WT and
AMPK-deﬁcient mice. Importantly, we found that muscle
glucose uptake during recovery from submaximal insulin
stimulation was not affected by acute loss of AMPK
activity in skeletal muscle (Supplementary Fig. 1B), dem-
onstrating that the diminished ability of AMPK-deﬁcient
mice to maintain elevated glucose uptake rates during
recovery is conﬁned to the contraction stimulus.
AMPK-Deﬁcient Mice Exhibit Intact Capacity for
Delivery, Transport, and Phosphorylation of Glucose in
Skeletal Muscle
Muscle glucose uptake has been shown to depend on
delivery, transport, and phosphorylation of glucose (10).
Delivery of glucose to themuscle is dependent on the blood
glucose concentration as well as blood ﬂow, and transport
and phosphorylation of glucose is dependent on GLUT4
and HKII protein abundance/activity, respectively. When
measuring blood glucose concentrations, we did not detect
differences between genotypes during and in recovery
from in situ contraction (Fig. 2A and Supplementary
Fig. 2A). Moreover, we found that the muscle protein
abundance of GLUT4 and HKII was not compromised in
AMPKa1a2 mdKO muscle (Fig. 2B, C, and F) but slightly
decreased in inducible AMPKa1a2 mdKO muscle com-
pared with WT muscle (Supplementary Fig. 2B and C).
Interestingly, measurements of the glucose metabolite
glucose-6-phosphate, an allosteric inhibitor of HKII activ-
ity, revealed decreased levels in muscle from AMPKa1a2
mdKO mice compared with WT mice in the period after
contraction (Fig. 2D). We suspect this to be a consequence
of the observed decrease in glucose uptake. Collectively,
these data suggest that the capacity to take up glucose into
muscle is similar between genotypes and that HKII activity
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and thus phosphorylation of glucose is likely not rate
limiting for glucose uptake after contraction in AMPK-
deﬁcient muscle. To exclude that the reduced glucose
uptake in AMPK-deﬁcient muscle after in vivo exercise
and in situ contraction was not due to a defect in glucose
delivery, we measured glucose uptake in isolated and in-
cubated EDL muscle from WT and AMPKa1a2 mdKO
mice. Compared with the rested muscle, we found that
glucose uptake was still increased 2 h after in situ con-
traction in incubated muscle from WT mice, whereas
glucose uptake had returned to resting levels in prior
contracted muscle from AMPKa1a2 mdKO mice (Fig.
2E). Together this suggests that the mechanism respon-
sible for maintaining elevated muscle glucose uptake after
exercise/contraction is located at the intracellular level.
AMPKActivity inWTMuscle Reverses toResting Levels
1 h After Contraction
Next we investigated whether the in situ contraction-
induced increase in AMPK activity was maintained into
Figure 1—Glucose uptake in the period after exercise and contraction is decreased in AMPK-deﬁcient skeletal muscle. A: In vivo glucose
uptake in EDL and TA muscle from AMPK mdKO mice (red bars) and WT littermates (black bars) at rest and 30 min after treadmill exercise
(rest, n = 3; exercise, n = 6–9). B and C: In vivo glucose uptake in TAmuscle from AMPKmdKOmice, AMPK imdKOmice (blue bars), andWT
littermates at rest, during in situ contraction, and 30 min and 1 h (only AMPKmdKOmice) after contraction (rest, n = 9–23; contraction, n = 4–
10; 30 min after contraction, n = 5–10; 1 h after contraction, n = 6). D and E: Glycogen content in TA muscle from AMPK mdKOmice, AMPK
imdKO mice, and WT littermates at rest and in response to 10 min in situ contraction (rest, n = 9–20; contraction, n = 4–10). F and G:
Phosphorylation of Erk1/2 Thr202/Tyr204 (AMPK mdKO) and P38MAPK Thr180/Tyr182 (AMPK imdKO) in TA muscle from AMPK-deﬁcient
mice and WT littermates at rest and in response to 10 min in situ contraction (rest, n = 9–20; contraction, n = 4–10). H: Representative
immunoblots. Signiﬁcantly different from WT is indicated as follows: ###P , 0.001, ##P , 0.01, and #P , 0.05. Signiﬁcantly different from
rest and 1 h after contraction is indicated as follows: ***P , 0.001. Signiﬁcantly different from rest, 30 min after contraction, and 1 h after
contraction is indicated as follows: §§§P , 0.001 and §§P , 0.01. Signiﬁcantly different from rest is indicated as follows: †††P , 0.001.
Statistical symbols presented in A, D, F, and G indicate main effect of intervention/genotype. Data in A–G are means 6 SEM.
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recovery, explaining greater glucose uptake in the period
after contraction. We observed that the AMPKa2b2g3-,
AMPKa2bg1-, and AMPKa1bg1-associated activity in WT
muscle had returned to resting levels 1 h after contraction
(Fig. 3A and Supplementary Fig. 3A and B). This was also
mirrored by measurements of phosphorylated AMPK
Thr172 and ACC Ser212 (Fig. 3B, C, and F and Supple-
mentary Fig. 3C and D). Thus, although AMPK seems to be
necessary for maintaining elevated muscle glucose uptake
in recovery from exercise and contraction, the mismatch
between AMPK activity and muscle glucose uptake 1 h
after contraction indicates that one or several proteins
regulated by AMPK and likely located closer to the GLUT4
recruitment event are responsible for maintaining higher
rates of glucose uptake in skeletal muscle after exercise and
contraction.
Glucose Uptake Is Decreased in TBC1D1-Deﬁcient
Muscle in Recovery From Contraction
Evidence indicates that AMPK-mediated glucose uptake
involves phosphoregulation of TBC1D1, which has been
suggested to increase GLUT4 translocation to the muscle
cell surface membrane (35). Interestingly, we found that
phosphorylation of AMPK downstream target TBC1D1
Ser231 was increased 30 min and 1 h after in situ con-
traction (Fig. 3D–F). Moreover, these ﬁndings were pos-
itively correlated with glucose uptake in WT muscle but not
in AMPK-deﬁcient muscle (Fig. 3G and H and Supplemen-
tary Fig. 3E and F). In comparison, we did not observe
associations between postcontraction glucose uptake and
phosphorylation of Akt2 downstream target TBC1D4
Thr649 (Supplementary Fig. 3G and H). We also observed
a small increase in phosphorylation of TBC1D1 Ser231 in
skeletal muscle from AMPK-deﬁcient mice after contrac-
tion. The reason for this is unclear, but it may be a con-
sequence of AMPK-independent effects of contraction in
muscle. Alternatively, contraction may lead to AMPK
activation and thus phosphorylation of TBC1D1 in non-
muscle cells that are present in the sample preparations of
whole skeletal muscle tissue.
To support the possible role of an AMPK-TBC1D1
signaling axis regulating muscle glucose uptake after
Figure 2—AMPK mdKO mice show normal capacity for glucose handling in skeletal muscle. A: Blood glucose concentration (mmol/L) in
AMPK mdKO mice (red bars) and WT littermates (black bars) during, 30 min after, and 1 h after in situ contraction (contraction, n = 15–21;
30 min after contraction, n = 24–30; 1 h after contraction, n = 18). B and C: GLUT4 and HKII protein abundance in TA muscle from AMPK
mdKOmice and WT littermates at rest, during in situ contraction, and 30 min and 1 h after contraction (rest, n = 19–23; contraction, n = 5–7;
30 min after contraction, n = 8–10; 1 h after contraction, n = 6). D: Glucose-6-phosphate (G-6-P) in TA muscle from AMPK mdKO mice and WT
littermates at rest, during in situ contraction, and 30min and 1 h after contraction (n = 4–6).E: Ex vivo glucose uptake in isolated and incubated
EDL muscle from AMPK mdKO mice and WT littermates 2 h after rest or prior in situ contraction (n = 3–4). F: Representative immunoblots.
Signiﬁcantly different from WT is indicated as follows: ###P , 0.001. Signiﬁcantly different from contraction and 30 min after contraction is
indicated as follows: †††P, 0.001. Signiﬁcantly different from rest and 30min after contraction is indicated as follows: ***P, 0.001 and *P,
0.05. Signiﬁcantly different from rest, 30 min after contraction, and 1 h after contraction is indicated as follows: §§P , 0.01. Statistical
symbols presented in A–C indicate main effect of intervention/genotype. Data in A–E are means 6 SEM.
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Figure 3—An AMPK-TBC1D1 signaling axis regulatesmuscle glucose uptake in the period after contraction. AMPKg3-associated activity (A)
and phosphorylation of AMPK Thr172 (B), ACC Ser212 (C ), and TBC1D1 Ser231 (D) in TA muscle from AMPKmdKOmice (red bars) and WT
littermates (black bars) at rest, during in situ contraction, and 30 min and 1 h after contraction (rest, n = 15–23; contraction, n = 5–7; 30 min
after contraction, n = 4–10; 1 h after contraction, n = 6). E: Phosphorylation of TBC1D1 Ser231 in TA muscle from AMPK imdKO mice (blue
bars) and WT littermates (black bars) at rest, during in situ contraction, and 30 min after contraction (rest, n = 9–20; contraction, n = 4–10;
30 min after contraction, n = 5–10). F: Representative immunoblots for B–E. Pearson correlations between glucose uptake and
phosphorylation of TBC1D1 Ser231 in TA muscle from WT littermates of AMPK mdKO (G) and AMPK imdKO mice (H) 30 min and 1 h
after in situ contraction (n = 16 and n = 6, respectively). R and signiﬁcance level are indicated in the respective panel. I: In vivo glucose uptake
in TA muscle from TBC1D1 KO mice (green bars) and WT littermates (black bars) at rest, during in situ contraction, and 30 min after
contraction (rest, n = 11–12; contraction, n = 6; 30 min after contraction, n = 5–6). J: The incremental increase (delta) in glucose uptake
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contraction, we next investigated glucose uptake both
during and after contraction in skeletal muscle from
TBC1D1 KO mice. Compared with WT littermates, we
found that the contraction-induced increase in glucose
uptake reversed faster in skeletal muscle from TBC1D1 KO
mice (Fig. 3I). This became even more apparent when
calculating the incremental increase (delta values for in-
dividual paired muscles) in glucose uptake during and
30 min after contraction (Fig. 3J). Importantly, the con-
traction-induced increase in phosphorylation of ACC
Ser212 was similar in skeletal muscle from both genotypes
(Fig. 3K and M), indicating that KO of TBC1D1 does not
compromise the ability of contraction to induce AMPK
signaling in skeletal muscle. As expected, contraction only
increased phosphorylation of TBC1D1 Ser231 in skeletal
muscle from WT littermates (Fig. 3L andM). As previously
reported (29), we found a ;50% reduction in GLUT4
protein abundance in skeletal muscle from TBC1D1 KO
mice (Supplementary Fig. 3I), which likely accounts for the
lesser increase in glucose uptake observed during in situ
contraction (Fig. 3I).
The Majority of Studies Reporting Decreased Glucose
Uptake in AMPK-Deﬁcient Muscle During Exercise/
Contractile Activity Measure Glucose Uptake in the
Recovery Period
To the best of our knowledge, 19 studies, including the
present one, have investigated glucose uptake in AMPK-
deﬁcient mouse skeletal muscle during exercise/contractile
activity by radioactive glucose tracer accumulation. In-
triguingly, 8 out of 10 studies reporting impaired contrac-
tion-induced glucose uptake in AMPK-deﬁcient muscle
actually measure glucose uptake in the period after con-
traction (Table 1). Such inconsistencies are also evident in
studies reporting impaired contraction-induced glucose
uptake in skeletal muscle from TBC1D1-deﬁcient mouse
models (Table 1). Collectively, these observations support
the notion of an AMPK-TBC1D1 signaling axis regulating
muscle glucose uptake in the period after exercise and
contraction.
DISCUSSION
AMPK has long been known for its ability to regulate muscle
glucose uptake based on numerous studies showing impaired
glucose uptake in AMPK-deﬁcient muscle when stimulated
with pharmacological AMPK agonists (18,23,28,36,37). Since
AMPK is activated in skeletal muscle during exercise and
contraction, common belief has been to assume that AMPK
regulates muscle glucose uptake under these conditions as
well. However, during the last 17 years, studies investigating
the role of AMPK in regulating muscle glucose uptake dur-
ing exercise and contraction have not been able to reach
consensus.
To address this matter, we carefully examined whether
the observed discrepancies in contraction-induced muscle
glucose uptake between different AMPK-deﬁcient mouse
models were due to circumstances related to the timing
of the uptake measurements. As a consequence, we per-
formed measurements of muscle glucose uptake assessed
by retroorbital injection of [3H]2-deoxyglucose during and
after exercise/contraction in two mouse models with skel-
etal muscle AMPK deﬁciency. Using this approach, we now
provide genetic evidence to support that AMPK regulates
muscle glucose uptake after, rather than during, exercise/
contraction. Based on these ﬁndings, we propose a model
by which activation of AMPK in skeletal muscle during
exercise acts to maintain a high glucose transport capacity
in recovery from exercise. We propose that AMPK in this
way secures a faster normalization of myocellular energy
and fuel status after contractile activity.
As contraction acutely increases AMPK activity in skel-
etal muscle (14,31,38), we investigated whether this effect
was maintained in recovery from contraction, potentially
explaining our ﬁndings on glucose uptake. Interestingly, in
WT skeletal muscle, we found that AMPK activity, as well
as phosphorylation of AMPK Thr172 and ACC Ser212, had
returned to resting levels 1 h after contraction, although
glucose uptake was still increased compared with rest-
ing levels. In contrast, phosphorylation of the AMPK
downstream target TBC1D1 was still increased 1 h after
contraction, demonstrating that distinct signaling down-
stream of AMPK as well as glucose uptake are sustained
for a long time during recovery even though AMPK activ-
ity is not. The reason for the apparent discrepancy be-
tween AMPK activity and downstream phosphorylation
of TBC1D1 is unclear. We speculate that it relates to
changes in phosphatase activity, altered cellular localiza-
tion of TBC1D1, or time-based dynamics in protein phos-
phorylation. Studies in humans have also reported
increased phosphorylation of TBC1D1 Ser231 in skeletal
muscle as long as 30–180 min after the cessation of
exercise (39,40). Interestingly, studies in rats and humans
(contraction/30 min after contraction values minus resting values) in TA muscle from TBC1D1 KO mice and WT littermates (n = 5–6).
Phosphorylation of ACC Ser212 (K) and TBC1D1 Ser231 (L) in TA muscle from TBC1D1 KO mice and WT littermates at rest, during in situ
contraction, and 30 min after contraction (rest, n = 11–12; contraction, n = 6; 30 min after contraction, n = 5–6). M: Representative
immunoblots. Signiﬁcantly different from WT is indicated as follows: ###P , 0.001 and ##P , 0.01. Signiﬁcantly different from rest, 30 min
after contraction, and 1 h after contraction is indicated as follows: ***P , 0.001 and *P , 0.05. Signiﬁcantly different from rest and 1 h after
contraction is indicated as follows: §§§P, 0.001, §§P, 0.01, and §P, 0.05. Signiﬁcantly different from rest is indicated as follows: †††P,
0.001, †P , 0.05, and (†)P = 0.066. Signiﬁcantly different from contraction is indicated as follows: ¶¶¶P , 0.001. Statistical symbols
presented in A–C indicate main effect of intervention/genotype. Data in A–E and I–L are means 6 SEM. ND, not detectable.
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report that both phosphorylation of TBC1D1 and muscle
glucose uptake return to pre-exercise levels 3–5 h in re-
covery from exercise (41–43). Collectively, these ﬁndings
suggest that phosphorylation of TBC1D1 and glucose
uptake decrease similarly in skeletal muscle after exercise
but that these two measures may not always track with
AMPK activity.
AMPK has been shown to target several proteins involved
in regulating muscle glucose uptake, including TBC1D4 and
PIKfyve (34,44). However, most evidence supports that
AMPK-mediated phosphorylation of TBC1D1 (and not
TBC1D4 and PIKfyve) facilitates AMPK-mediated effects on
muscle glucose uptake (35,45). We found that phosphoryla-
tion of TBC1D1 is likely not important for regulating muscle
glucose uptake during contraction, as phosphorylation of
TBC1D1 was severely impaired in AMPK-deﬁcient muscle
even though contraction-induced glucose uptake was not. In
contrast, we found that phosphorylation of TBC1D1 Ser231
in the period after contraction was positively associated with
glucose uptake. Since this association was found in WT
muscle only, this could indicate that AMPK phosphorylates
TBC1D1 during exercise/contraction to securemuscle glucose
uptake in the period after exercise/contraction. In support of
this, we found that increased rates of glucose uptake in
skeletal muscle after contraction were dependent on the
presence of TBC1D1 as the contraction-induced increase
in glucose uptake reversed faster in TBC1D1-deﬁcient muscle
compared withWTmuscle. Because glycolytic skeletal muscle
from TBC1D1 KO mice exhibits a loss in GLUT4 protein
content (29), this likely accounts for the minor decrease in
muscle glucose uptake observed during contraction. This is
also supported by the observation that while exercise-induced
glucose uptake is impaired in glycolytic quadriceps muscle
from TBC1D1 KO mice, such a defect is not observed in
oxidative quadriceps muscle, which expresses normal lev-
els of GLUT4 protein content compared with muscle from
WT littermates (46).
Going through the literature, we noticed that the
majority of studies reporting impaired exercise/contrac-
tion-induced glucose uptake in AMPK-deﬁcient muscle
had unintentionally been measuring glucose uptake in
recovery from exercise/contraction (Table 1), support-
ing the idea of AMPK being a regulator of muscle glucose
uptake in the period after exercise/contraction. Never-
theless, some studies have reported intact contraction-
induced glucose uptake in AMPK-deﬁcient muscle al-
though measurements of glucose uptake were performed in
recovery (18,21,37,47–49), whereas others have reported
impaired contraction-induced glucose uptake in AMPK-
deﬁcient muscle when measurements of glucose uptake were
performed during contraction (50,51). These ﬁndings, how-
ever, may be related to incomplete KO of AMPK activity in
skeletal muscle as KO of single catalytic subunits of AMPK
has been shown to increase the activity of the remaining
catalytic subunit during contractile activity (14). Also, sec-
ondary adaptations leading, for example, to reduced force
production and reduced mitochondrial content in skeletal
muscle from AMPK-deﬁcient mice may have masked the
likely function of AMPK in regulating muscle glucose uptake
after contraction (Table 1). We cannot ultimately rule out
that AMPK may be necessary for regulating muscle glucose
uptake during longer periods of exercise (.30 min) and
contraction (.10 min) where the myocellular stress may be
further elevated. However, measurements of skeletal muscle
glucose uptake in AMPK kinase-dead mice and AMPKa1a2
mdKO mice during longer periods of contraction (20 min)
(52) and in vivo exercise (90 min) (J.R. Hingst, J.F.P.W.,
unpublished observations), respectively, argue against this
idea.
Only a few studies have investigated whether TBC1D1
may be involved in regulating exercise/contraction-
induced glucose uptake in skeletal muscle. Interestingly,
two studies using gene electrotransfer into mouse TA
muscle leading to overexpression of TBC1D1 mutated at
several predicted AMPK phosphorylation sites report
a 22% and 42% reduction in contraction-stimulated glu-
cose uptake without a change in GLUT4 protein abundance
between muscles transfected with control or mutated
TBC1D1 (35,45). However, in both studies, muscle glucose
uptake rates were measured as the combined uptake of
glucose during (15 min) and after (30 min) contraction.
Based on the ﬁndings presented here, this may suggest
that the observed impairment in contraction-induced glu-
cose uptake in skeletal muscle transfected with mutated
TBC1D1 was due to measurements of glucose uptake rates
in the recovery period from contraction.
If we permit translation of our observations in mice to
human physiology, this may in fact bring some new aspects
into former human observations. First, it has been shown
that the activation of AMPK in human skeletal muscle in
response to exercise (53–55) is not reversed immediately
after exercise but is maintained above basal levels for
a prolonged period of time. In some studies, this is evident
from enhanced AMPK activity per se (40,54,56) and in
other studies from enhanced AMPK downstream signaling
(57,58). Thus, it would be expected that inmuscle of humans,
the sarcolemmal glucose transport capacity is maintained
high in the period after exercise. Apparently this view con-
ﬂicts with the observation that muscle glucose uptake quickly
reverses to resting levels shortly after exercise (3,59). How-
ever, the reversal of glucose uptake is likely the result of
a marked decrease in muscle perfusion (delivery) (60) rather
than a decrease in sarcolemmal glucose permeability. This
interpretation may be inferred from a study in which the
muscular interstitial glucose concentration was measured in
the period after exercise. Thus, several hours into recovery
from one-legged exercise, the interstitial muscle glucose con-
centration was markedly lower in the prior exercised leg
(;1.85 mmol/L) compared with the rested leg (;4.13
mmol/L) despite comparable blood ﬂow to the two legs
(61). Therefore we now propose that the maintained mem-
brane glucose permeability in human skeletal muscle relates
to elevated AMPK activity and downstream signaling in
the recovery period from exercise. The enhanced glucose
diabetes.diabetesjournals.org Kjøbsted and Associates 1437
permeability is thus favoring glucose uptake in previously
exercised muscle once delivery of glucose (perfusion/plasma
concentration) increases, for example, upon food intake and
subsequent insulin release.
In conclusion, by measurements of muscle glucose uptake
during and in recovery from exercise/contraction and careful
evaluation of the literature, our ﬁndings provide new means
of AMPK for the regulation of muscle glucose uptake. Our
study seems to explain the large discrepancy that occurred in
the aftermath of the seminal observation by Mu et al. (23) in
2001, indicating a role of AMPK in regulating muscle glucose
uptake during contractile activity. Hence, it appears that the
acute activation of AMPK in skeletal muscle during exercise/
contraction acts to secure glucose uptake when the contrac-
tile activity ceases. This provides a mechanism by which
a high glucose transport capacity is secured, favoring re-
plenishment of muscle cellular energy stores after exercise/
contraction. An important premise for this interpretation, if
indeed AMPK functions to delay GLUT4 endocytosis in
skeletal muscle (24), is that the stimuli leading to enhanced
GLUT4 exocytosis prevail over GLUT4 endocytosis in regu-
lating GLUT4 content at the cell surface membrane during
exercise and contraction where AMPK activity is also ele-
vated. Although debatable, such stimuli may include entry of
extracellular Ca2+ as well as mechanical stress signaling
(11,62). Together with our previous ﬁndings, revealing
a role of AMPK in regulating muscle insulin sensitivity after
exercise and contraction (31), the current study identiﬁes
AMPK as an important regulator of muscle glucose metab-
olism after, rather than during, exercise/contraction.
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